ABCG2 and breast carcinoma: No influence in anthracycline pharmacokinetics was reported with ABCG2 in an AML cohort with daunorubicin (rs2231137, rs2231142, rs769188) [69] or a breast cancer cohort with doxorubicin (rs2231142) [47].